Patents by Inventor Matteo Longhi

Matteo Longhi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors
    Patent number: 11440922
    Abstract: This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 13, 2022
    Assignee: Recordati Industria Chimica e Farmacentica S.p.A.
    Inventors: Carlo Riva, Davide Graziani, Matteo Longhi, Elisa Callegari, Fabio Frigerio, Patrizia Angelico
  • HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS
    Publication number: 20200347078
    Abstract: This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.
    Type: Application
    Filed: June 29, 2018
    Publication date: November 5, 2020
    Inventors: Carlo RIVA, Davide GRAZIANI, Matteo LONGHI, Elisa CALLEGARI, Fabio FRIGERIO, Patrizia ANGELICO
  • Heterocyclic derivatives as M-GLU5 antagonists
    Patent number: 8518916
    Abstract: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: August 27, 2013
    Assignee: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani, Matteo Longhi
  • NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS
    Publication number: 20090042841
    Abstract: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).
    Type: Application
    Filed: August 4, 2008
    Publication date: February 12, 2009
    Applicant: Recordati Ireland Limited
    Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani, Matteo Longhi